Coherus BioSciences, Inc. said the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (IPR) of AbbVie’s US patent 8,889,135.
“The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40mg of Humira subcutaneously every 13 to 15 days,” said Coherus.
Coherus CEO Denny Lanfear said: “We are pleased that the PTAB has decided to invalidate all claims of the ‘135 patent
“While more remains to be done, this is a significant step forward to lowering drug costs for patients and healthcare providers in the US system.
“This case unmistakably demonstrates the value of the Inter Partes Review process and the need to preserve the IPR process to enable review of patents that may inappropriately extend market exclusivity and prevent needed competition.
“We believe this successful outcome validates Coherus’ leadership in biosimilar intellectual property and the effectiveness of our platform.
“We will continue to aggressively press forward with the development and commercialization of our CHS-1420 adalimumab biosimilar consistent with our corporate strategy.”